Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study

Abstract

Abstract Background Immunocompromised cancer patients are presumed to be at high risk of developing COVID-19 infection. Predisposing factors to contracting COVID-19 and to severe outcomes have been described in registries but were not compared between solid tumors and hematological malignancies. Method This retrospective single oncologic center study included adults with solid tumors or hematological malignancies referred to testing by naso-pharyngeal swab for a SARS-CoV-2 RT-PCR from March 10 to May 18, 2020. Results A total of 212 patients were included in the study. Forty-five (21%) were tested positive with SARS-CoV-2. The univariate analysis with positive SARS-CoV-2 PCR as a dependent variable reveals significant odds ratios (ORs) for age—with a mean of 62.5 years—(OR: 1.05, 95% CI: 1.02–1.08), performance status ≥2 (OR: 2.38, 95% CI: 1.22–4.70), inpatient status (OR: 2.36, 95%CI: 1.11–4.91), and hematological malignancies (OR: 2.48, 95% CI: 1.23–4.96). In contrast, OR for solid tumors reveals a negative association (OR: 0.40, 95% CI: 0.20–0.81). When integrating severe outcome (ICU admission or COVID-19-related death) as a dependent variable, the univariate logistic regression model shows significant ORs for pre-existing lymphopenia (OR: 4.0, 95% CI: 1.17–15.04), hematological malignancies (OR: 3.73, 95% CI: 1.09–13.80), and a negative association for solid tumors (OR: 0.27; 95% CI: 0.07–0.92). Conclusion In patients referred for SARS-CoV-2 testing, hematological malignancies were associated with a higher risk of COVID-19 infection and severe outcomes. Other factors were age and inpatient status.